Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KZR 
Kezar Life Sciences Inc (KZR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KZR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 3 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.49% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.46M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 6 | Beta 0.57 | 52 Weeks Range 3.62 - 9.18 | Updated Date 06/30/2025 |
52 Weeks Range 3.62 - 9.18 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.22 |
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -2.65 | Actual -2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32% | Return on Equity (TTM) -57.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -66498204 | Price to Sales(TTM) 6.03 |
Enterprise Value -66498204 | Price to Sales(TTM) 6.03 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.06 | Shares Outstanding 7305800 | Shares Floating 4902630 |
Shares Outstanding 7305800 | Shares Floating 4902630 | ||
Percent Insiders 11.57 | Percent Institutions 59.28 |
Analyst Ratings
Rating 3 | Target Price 12.5 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kezar Life Sciences Inc
Company Overview
History and Background
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company founded in 2015. It focuses on discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune diseases and cancer.
Core Business Areas
- Autoimmune Disease Therapies: Developing treatments for autoimmune diseases, focusing on protein degradation and immune regulation.
- Oncology Therapies: Developing treatments for various cancers through selective kinase inhibition.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- ZONTAL (Vazalore): An investigational selective inhibitor of immunoproteasome, currently in Phase 3 trials for lupus nephritis. It aims to address inflammation. Competitors include existing immunosuppressants and biologics such as Benlysta (GSK) and Lupkynis (Aurinia Pharmaceuticals).
- KZR-261: A preclinical stage program focused on inhibiting Sec61, a protein channel essential for protein secretion. It targets protein secretion. Competitors include existing proteasome inhibitors and drugs affecting protein synthesis.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, driven by innovation and regulatory approvals. Demand for novel therapies for autoimmune diseases and cancer is high.
Positioning
Kezar is positioned as an innovative biotech company focused on targeted therapies for immune-mediated diseases and cancer. Its competitive advantage lies in its unique drug candidates and targeted approach to protein degradation and secretion.
Total Addressable Market (TAM)
The TAM for autoimmune disease and cancer therapies is estimated to be in the hundreds of billions of dollars. Kezar's positioning focuses on niche segments within these markets.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced leadership team
- Targeted approach to protein degradation and secretion
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- Dependence on clinical trial success
- Reliance on external funding
- High cash burn rate
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- GSK
- Aurinia Pharmaceuticals
- Johnson & Johnson
- AbbVie
- Bristol Myers Squibb
Competitive Landscape
Kezar faces competition from established pharmaceutical companies with larger resources and marketed products. Its advantage is its focus on novel targets and its potential to address unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Kezar's growth is tied to clinical trial milestones and regulatory approvals.
Future Projections: Future growth projections are dependent on the success of ZONTAL and KZR-261. Analyst estimates vary based on clinical trial data.
Recent Initiatives: Recent initiatives include advancing ZONTAL through Phase 3 trials, and advancing other early-stage clinical programs. They are actively engaged in investor relations and presentations.
Summary
Kezar Life Sciences is a promising biotech company focused on developing novel therapies for autoimmune diseases and cancer. The company's success hinges on the outcomes of its clinical trials, especially ZONTAL. Key challenges include managing cash flow, navigating regulatory hurdles, and competing with larger, established pharmaceutical companies. Recent initiatives, such as advancing ZONTAL, are critical for its future growth and value creation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kezar Life Sciences Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kezar Life Sciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-06-21 | Co-Founder, CEO & Director Dr. Christopher J. Kirk Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | |
Full time employees 55 | |||
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.